Zusammenfassung
Pleiotrope Substanzen sind durch ihr ausgesprochen vielfältiges und komplexes Wirkspektrum charakterisiert und dies macht sie für die Therapie von Wunden attraktiv. Neben seinem bekannten Effekt der Steigerung der Hämatopoese konnte das Glykoproteinhormon Erythropoietin (EPO) in diversen anderen Organen eine deutliche Gewebeprotektion aufzeigen. Der Einsatz von EPO im Rahmen von Regenerationsprozessen der Haut basiert hier wahrscheinlich im Wesentlichen auf seiner zytoprotektiven, proangiogenen, antiapoptotischen sowie antiinflammatorischen Wirksamkeit. Hier kann EPO durch eine niedrigdosierte bzw. einmalige Applikation die strukturelle und koordinierte Interaktion verschiendener Zelltypen untereinander stimulieren. Diese Übersichtsarbeit soll die Vor- und Nachteile einer EPO-Gabe im Rahmen verschiedener Heilungs- und Regenerationsvorgänge der Haut aus der experimentellen Forschung beleuchten und mögliche klinische Anwendungen diskutieren.
Abstract
Pleiotropic substances are characterized by their versatile and complex range of actions which makes them potential new active agents for the therapy of wounds. Besides its known effect to increase red blood cell production, the glycoprotein hormone erythropoietin (EPO) has been found to demonstrate a tissue protective effect in several other organs. The administration of EPO during skin wound healing is most likely essentially based on its cytopotective, proangiogenic, antiapoptotic and antiinflammatory effects. Herein EPO stimulates a coordinated interaction of different types of cells at a low or only a single dose. This review article aims to present the advantages and disadvantages of EPO administration in different experimental models to study the healing and regeneration processes of the skin and discusses possible clinical applications.
Literatur
Bodó E, Kromminga A, Funk W et al (2007) Human hair follicles are an extrarenal source and a nonhematopoietic target of erythropoietin. FASEB J 21:3346–3354
Bonsdorff E, Jalavisto E (1948) A humoral mechanism in anoxic erythrocytosis. Acta Physiol Scand 16:150–170
Buemi M, Galeano M, Sturiale A et al (2004) Recombinant human erythropoietin stimulates angiogenesis and healing of ischemic skin wounds. Shock 22:169–173
Buemi M, Lacquaniti A, Bolignano D et al (2009) Down with the erythropoietin. Long live the erythropoietin! Curr Drug Targets 10:1028–1032
Carnot P, Deflandre C (1906) Sur l‘activité hémopoiétique du sérum au cours de la régénération du sang. C R Acad Sci 143:384–386
Desmouliere A, Badid C, Lochaton-Piallat BM, Gabbiani G (1997) Apoptosis during wound healing, fibrocontractive diseases and vascular wall injury. Int J Biochem Cell Biol 29:19–30
Drüeke TB, Locatelli F, Clyne N et al (2006) Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 355:2071–2084
Erbayraktar Z, Erbayraktar S, Yilmaz O et al (2009) Nonerythropoietic tissue protective compounds are highly effective facilitators of wound healing. Mol Med 15:235–241
Fatouros MS, Vekinis G, Bourantas KL et al (1999) Influence of growth factors erythropoietin and granulocyte macrophage colony stimulating factor on mechanical strength and healing of colonic anastomoses in rats. Eur J Surg 165:986–992
Ferri C, Giuggioli D, Sebastiani M, Colaci M (2007) Treatment of severe scleroderma skin ulcers with recombinant human erythropoietin. Clin Exp Dermatol 32:287–290
Fishbane S, Ragolia L, Palaia T et al (2004) Cytoprotection by darbepoetin/epoetin alfa in pig tubular and mouse mesangial cells. Kidney Int 65:452–458
Gaillard N, Mania A, Brunel H et al (2009) Interferon-alfa- and erythropoetin-associated cerebral vasoconstriction. Cephalalgia 29:1340–1343
Galeano M, Altavilla D, Bitto A et al (2006) Recombinant human erythropoietin improves angiogenesis and wound healing in experimental burn wounds. Crit Care Med 34:1139–1146
Galeano M, Altavilla D, Cucinotta D et al (2004) Recombinant human erythropoietin stimulates angiogenesis and wound healing in the genetically diabetic mouse. Diabetes 53:2509–2517
Ghezzi P, Brines M (2004) Erythropoietin as an antiapoptotic, tissue-protective cytokine. Cell Death Differ 11(Suppl 1):37–44
Greenhalgh DG (1998) The role of apoptosis in wound healing. Int J Biochem Cell Biol 30:1019–1030
Haroon ZA, Amin K, Jiang X, Arcasoy MO (2003) A novel role for erythropoietin during fibrin-induced wound-healing response. Am J Pathol 163:993–1000
Huang J, Li CY, Mesa RA et al (2008) Risk factors for leukemic transformation in patients with primary myelofibrosis. Cancer 112:2726–2732
Jelkmann W (2000) Use of recombinant human erythropoietin as an antianemic and performance enhancing drug. Curr Pharm Biotechnol 1:11–31
Keast DH, Fraser C (2004) Treatment of chronic skin ulcers in individuals with anemia of chronic disease using recombinant human erythropoietin (EPO): a review of four cases. Ostomy Wound Manage 50:64–70
Le Minh K, Klemm K, Abshagen K et al (2007) Attenuation of inflammation and apoptosis by pre- and posttreatment of darbepoetin-alpha in acute liver failure of mice. Am J Pathol 170:1954–1963
Löser M (2008) Synthese und Sekretion von Erythropoetin durch genetisch modifizierte Zellen der Haut. Dissertation Ludwig-Maximilians-Universität München
Quaschning T, Ruschitzka F, Stallmach T et al (2003) Erythropoietin-induced excessive erythrocytosis activates the tissue endothelin system in mice. FASEB J 17:259–261
Ribatti D, Presta M, Vacca A et al (1999) Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Blood 93:2627–2636
Sakanaka M, Wen TC, Matsuda S et al (1998) In vivo evidence that erythropoietin protects neurons from ischemic damage. Proc Natl Acad Sci U S A 95:4635–4640
Saray A, Ozakpinar R, Koc C et al (2003) Effect of chronic and short-term erythropoietin treatment on random flap survival in rats: an experimental study. Laryngoscope 113:85–89
Savino R, Ciliberto G (2004) A paradigm shift for erythropoietin: no longer a special ized growth factor, but rather an all-purpose tissue-protective agent. Cell Death Differ 11(Suppl 1):2–4
Sorg H, Krueger C, Schulz T et al (2009) Effects of erythropoietin in skin wound healing are dose related. FASEB J 23:3049–3058
Vachharajani V, Vital S, Russell J (2010) Modulation of circulating cell-endothelial cell interaction by erythropoietin in lean and obese mice with cecal ligation and puncture. Pathophysiology 17:9–18
Vaziri ND (2001) Cardiovascular effects of erythropoietin and anemia correction. Curr Opin Nephrol Hypertens 10:633–637
Wish JB, Coyne DW (2007) Use of erythropoiesis-stimulating agents in patients with anemia of chronic kidney disease: overcoming the pharmacological and pharmacoeconomic limitations of existing therapies. Mayo Clin Proc 82:1371–1380
Interessenkonflikt
Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sorg, H., Kuhbier, J., Menger, B. et al. Die Rolle von Erythropoietin bei der Verbesserung der Wundheilung. Chirurg 81, 993–998 (2010). https://doi.org/10.1007/s00104-010-1978-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00104-010-1978-3